What we do
Equity products
Technology Transfer
European Angels Fund (EAF) - Co-investments with Business Angels
Venture capital
The Social Impact Accelerator (SIA)
Lower mid-market
Mezzanine Facility for Growth
Pan-European Venture Capital Fund(s)-of-Funds programme
EFSI Equity instrument
Single EU Equity Financial Instrument
COSME - Equity Facility for Growth
InnovFin Equity
Private equity secondary market transactions
EIF-NPI Equity Platform
Debt products
AGRI Guarantee Facility
AGRI Italy Platform Uncapped Guarantee Instrument
Credit enhancement
Cultural and Creative Sectors Guarantee Facility (CCS GF)
ENSI - Securitisation Initiative
Erasmus+ Master Loan Guarantee Facility
EREM debt products
Single EU Debt Financial Instrument
COSME - Loan Guarantee Facility
InnovFin SME Guarantee Facility
Documentary Finance Facility – Bulgaria
The SME Initiative
The SME Initiative Bulgaria
The SME Initiative Finland
The SME Initiative Italy
The SME Initiative Malta
The SME Initiative Romania
The SME Initiative Spain
Asset Management Umbrella Fund (AMUF)
Inclusive finance
EaSI Financial Instruments
EaSI Capacity Building Investments Window
EaSI Guarantee Instrument
European Progress Microfinance Facility
Entrepreneurs supported through Progress Microfinance
European Fund for Strategic Investments (EFSI)
How does EIF contribute to EFSI
How to apply for EFSI financing
Regional Development - Country and sector-specific initiatives
AGRI Italy Platform Uncapped Guarantee Instrument
ALTER’NA – ESIF EARFD Nouvelle-Aquitaine
Baltic Innovation Fund (BIF)
Central Europe Fund of Funds (CEFoF)
Croatian Venture Capital Initiative (CVCi FoF)
Deep and Comprehensive Free Trade Area Initiative East Guarantee Facility (DCFTA)
Dutch Growth Co-Investment Programme
Dutch Venture Initiative (DVI-II)
EAFRD FoF Romania
European Recovery Programme (ERP)
ERP-EIF Co-Investment Growth Facility
Competitiveness Fund-of-Funds for SMEs in Romania
Regional Fund-of-Funds Romania
ESIF Fund-of-Funds Czech Republic
ESIF Fund-of-Funds Greece
The Silesia EIF Fund of Funds
La Financière Région Réunion
The EIB Group Risk Enhancement Mandate (EREM)
Greater Anatolia Guarantee Facility (GAGF)
G43 - Anatolian Venture Capital Fund Project
LfA-EIF Facility
Luxembourg Future Fund (LFF)
Mezzanine 'Fund of Fund' for Germany (MDD)
Polish Growth Fund of Funds (PGFF)
Scottish-European Growth Co-Investment Programme
Slovene Equity Growth Investment Programme (SEGIP)
Swedish Venture Initiative (SVI)
Turkish Growth and Innovation Fund (TGIF)
Western Balkans Enterprise Development & Innovation Facility (WB EDIF)

UK FTF supports future technologies and entrepreneurship once more

    Date: 24 November 2010

The UK Future Technologies Fund (UK FTF) has committed £15 million into Advent Venture Partner’s first life science focused fund, to be called Advent Life Sciences.  This is UK FTF’s third signature with the objective to support technology-based small and medium sized businesses (SME) since its launch in February 2010.

Advent Life Science’s investment strategy is a perfect fit with UK FTF’s stage and sector target.  It specifically concentrates on innovative early- to mid-stage UK and European companies that provide technologies or products in a range of sectors within life sciences, including new drug discovery, enabling technologies, med tech and diagnostics.

The Advent team managing the fund has been involved in SME financing in the advanced technologies sector for over 20 years and has extensive market knowledge, experience and recognition which make them one of the major and most established players on the UK venture capital market.

“This investment is exactly why UK FTF was set up - to back venture capital fund managers that have the capacity to make a difference to the technology and innovation sectors, that will pick, support, develop and transform UK businesses into European forerunners and that are able to create momentum and traction to close funds in a challenging market environment” says John Holloway Transaction and Relationship Management Director at the European Investment Fund (EIF).

“We are convinced that our renewed cooperation with Advent will have a significant impact on the development of UK’s future technologies”.

About UK FTF

The UK Future Technologies Fund (UK FTF) is one of two funds of funds which effectively make up the UK Innovation Investment Fund (UK IIF) 

Backed by a £150m investment from the Department for Business, Innovation and Skills, the Department of Energy and Climate Change, and the Department of Health, UK IIF has already attracted outside investment to more than match this amount with the total first closing of £325m. 

The UK FTF, managed by EIF, has £200 million to invest. This Fund of Funds invests in a range of technologies such as life sciences, digital technology, and advanced manufacturing. 

About EIF

EIFs’ central mission is to support Europe's SMEs by helping them to access finance.  EIF designs and develops venture capital and guarantees instruments which specifically target this market segment. EIF has a crucial role to play throughout the value chain of enterprise creation, from the earliest stages of intellectual property development to mid and later stages SMEs. EIF fosters EU objectives in support of innovation, research and regional development, entrepreneurship, growth, and employment.

For further information on UK FTF please follow this link

For information on the signature please contact Jean-François Leprince, LEPRINCE@eif.org (Investment Manager) or contact Joëlle Harvey, j.harvey@eif.org (Public Relations)

About Advent Venture Partners 

Advent Venture Partners is one of Europe’s most established growth and venture capital firms, investing in technology and life sciences businesses run by great teams that want a pragmatic and well-connected partner by their side. 

The Advent life sciences team is a leader in European life sciences venture capital.  Its investments  include: PowderMed, a therapeutic DNA vaccine company sold to Pfizer; Thiakis, an obesity treatment company acquired by Wyeth Pharmaceuticals; Respivert, a drug discovery company focused on respiratory diseases that was acquired by Johnson & Johnson; Cellnovo, a biomedical device company developing a revolutionary mobile insulin pump system; EUSA Pharma, a rapidly growing transatlantic speciality pharmaceutical company focused on late-stage oncology, pain control and critical care products; and, Algeta (ALGETA.OL), an oncology company developing treatments for bone metastases and disseminated tumour types.



Copyright ©

 European Investment Fund 2017 – The European Investment Fund is not responsible for the content of external internet sites.